OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Trial details
- Registry ID
- NCT06016738
- Drugs studied
- Anastrozole, Exemestane, Fulvestrant, Letrozole and 1 more
TrialRedline tracks 1 clinical trial sponsored by Olema Pharmaceuticals, Inc.: 1 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 | Anastrozole, Exemestane, Fulvestrant, Letrozole and 1 more | Active not recruiting | 2026-10-31Estimated |
Names as written in the registry records.
NCT06016738 · Olema Pharmaceuticals, Inc.
Before: 30 Jun 2026. After: 31 Oct 2026.
Before: Recruiting. After: Active not recruiting.